(L773:1527 2729 OR L773:1534 6277)
Search: (L773:1527 2729 OR L773:1534 6277) > Long-Term Effect of...
- 2 of 7
- Previous record
- Next record
- To hitlist
Long-Term Effect of Cranial Radiotherapy on Pituitary-Hypothalamus Area in Childhood Acute Lymphoblastic Leukemia Survivors
-
- Follin, Cecilia (author)
- Lund University,Lunds universitet,Endokrin,Forskargrupper vid Lunds universitet,Endocrine,Lund University Research Groups,Skåne University Hospital
-
- Erfurth, Eva Marie (author)
- Lund University,Lunds universitet,Medicin/akutsjukvård, Lund,Sektion II,Institutionen för kliniska vetenskaper, Lund,Medicinska fakulteten,Medicine, Lund,Section II,Department of Clinical Sciences, Lund,Faculty of Medicine,Skåne University Hospital
- (creator_code:org_t)
- 2016-07-30
- 2016
- English.
- In: Current Treatment Options in Oncology. - : Springer Science and Business Media LLC. - 1527-2729 .- 1534-6277. ; 17:9
- Journal article (peer-reviewed)
Abstract
Subject headings
Close
- Survival rates of childhood cancer have improved markedly, and today more than 80 % of those diagnosed with a pediatric malignancy will become 5-year survivors. Nevertheless, survivors exposed to cranial radiotherapy (CRT) are at particularly high risk for long-term morbidity, such as endocrine insufficiencies, metabolic complications, and cardiovascular morbidity. Deficiencies of one or more anterior pituitary hormones have been described following therapeutic CRT for primary brain tumors, nasopharyngeal tumors, and following prophylactic CRT for childhood acute lymphoblastic leukemia (ALL). Studies have consistently shown a strong correlation between the total radiation dose and the development of pituitary deficits. Further, age at treatment and also time since treatment has strong implications on pituitary hormone deficiencies. There is evidence that the hypothalamus is more radiosensitive than the pituitary and is damaged by lower doses of CRT. With doses of CRT 50 Gy) may produce direct anterior pituitary damage, which contributes to multiple pituitary deficiencies. The large group of ALL survivors treated with CRT in the 70–80-ties has now reached adulthood, and these survivors were treated mainly with 24 Gy, and the vast majority of these patients suffer from GHD. Further, after long-term follow-up, insufficiencies in prolactin (PRL) and thyroid stimulating hormone (TSH) have also been reported and a proportion of these patients were also adrenocoticotrophic hormone (ACTH) deficient. CRT to the hypothalamus causes neuroendocrine dysfunction, which means that the choice of GH test is crucial for the diagnosis of GHD.
Subject headings
- MEDICIN OCH HÄLSOVETENSKAP -- Klinisk medicin -- Cancer och onkologi (hsv//swe)
- MEDICAL AND HEALTH SCIENCES -- Clinical Medicine -- Cancer and Oncology (hsv//eng)
Keyword
- Adrenocorticotrophic hormone
- Childhood acute lymphoblastic leukemia
- Cranial radiotherapy
- Gonadotropin
- Growth hormone
- Hypothalamic-pituitary axis
- Late complications
- Pituitary hormone deficiency
- Prolactin
- Thyroid stimulating hormone
Publication and Content Type
- art (subject category)
- ref (subject category)
Find in a library
- Current Treatment Options in Oncology (Search for host publication in LIBRIS)
To the university's database
- 2 of 7
- Previous record
- Next record
- To hitlist
Find more in SwePub
- By the author/editor
- Follin, Cecilia
- Erfurth, Eva Mar ...
- About the subject
-
- MEDICAL AND HEALTH SCIENCES
- MEDICAL AND HEAL ...
- and Clinical Medicin ...
- and Cancer and Oncol ...
- Articles in the publication
- Current Treatmen ...
- By the university
- Lund University
Search outside SwePub
- Extend your search to:
- Google Book Search
- Google Scholar
Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.
- Copyright © LIBRIS - National Library Systems
- LIBRIS.kb.se
